📊 PASG Key Takeaways
Is Passage BIO, Inc. (PASG) a Good Investment?
Passage BIO is a pre-revenue biotech company with significant operating losses (-$49.3M) and annual cash burn of -$31.5M, providing approximately 18 months of runway at current burn rates despite holding $46.3M in cash. The company exhibits fundamentally unsustainable unit economics with negative ROE of -242.7% and ROA of -73.1%, lacking any revenue generation to offset R&D expenses.
Why Buy Passage BIO, Inc. Stock? PASG Key Strengths
- Strong absolute cash position of $46.3M relative to total assets ($62.3M)
- Healthy short-term liquidity with current ratio of 2.07x and no long-term debt
- Operating in biologics sector with potential upside if development programs succeed
PASG Stock Risks: Passage BIO, Inc. Investment Risks
- Zero revenue with no clear path to commercialization in near term
- Unsustainable cash burn rate of -$31.5M annually providing limited runway (~18 months)
- Deeply negative returns on equity (-242.7%) and assets (-73.1%) indicating value destruction
- Development-stage biotech with significant clinical and regulatory execution risk
- Complete dependence on future capital raises to continue operations
Key Metrics to Watch
- Cash runway and quarterly cash burn rate trends
- Clinical trial progress and regulatory milestones for pipeline programs
- Capital raise announcements and dilution to existing shareholders
Passage BIO, Inc. (PASG) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.07x current ratio provides a solid financial cushion.
PASG Profit Margin, ROE & Profitability Analysis
PASG vs Healthcare Sector: How Passage BIO, Inc. Compares
How Passage BIO, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Passage BIO, Inc. Stock Overvalued? PASG Valuation Analysis 2026
Based on fundamental analysis, Passage BIO, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Passage BIO, Inc. Balance Sheet: PASG Debt, Cash & Liquidity
PASG Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Passage BIO, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-21.04 indicates the company is currently unprofitable.
PASG Revenue Growth, EPS Growth & YoY Performance
Passage BIO, Inc. Dividends, Buybacks & Capital Allocation
PASG SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Passage BIO, Inc. (CIK: 0001787297)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PASG
What is the AI rating for PASG?
Passage BIO, Inc. (PASG) has an AI rating of STRONG SELL with 80% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PASG's key strengths?
Claude: Strong absolute cash position of $46.3M relative to total assets ($62.3M). Healthy short-term liquidity with current ratio of 2.07x and no long-term debt.
What are the risks of investing in PASG?
Claude: Zero revenue with no clear path to commercialization in near term. Unsustainable cash burn rate of -$31.5M annually providing limited runway (~18 months).
What is PASG's revenue and growth?
Passage BIO, Inc. reported revenue of N/A.
Does PASG pay dividends?
Passage BIO, Inc. does not currently pay dividends.
Where can I find PASG SEC filings?
Official SEC filings for Passage BIO, Inc. (CIK: 0001787297) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PASG's EPS?
Passage BIO, Inc. has a diluted EPS of $-14.35.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PASG a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Passage BIO, Inc. has a STRONG SELL rating with 80% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PASG stock overvalued or undervalued?
Valuation metrics for PASG: ROE of -242.7% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PASG stock in 2026?
Our dual AI analysis gives Passage BIO, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PASG's free cash flow?
Passage BIO, Inc.'s operating cash flow is $-31.5M, with capital expenditures of $34.0K.
How does PASG compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -242.7% (avg: 15%), current ratio 2.07 (avg: 2).